SCHEMBL212911

SCHEMBL212911

CC(=O)ON=C(C)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.60
PKM P14618 1/20 0.60
CDK5 Q00535 1/20 0.60
CDK5R1 Q15078 1/20 0.60
MAPK1 P28482 2/20 0.57
LMNA P02545 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
HTT P42858 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
ALDH1A1 P00352 1/20 0.52
CYP1A2 P05177 2/20 0.50
CYP2D6 P10635 1/20 0.50
HSD17B10 Q99714 1/20 0.50
POLB P06746 1/20 0.50
HPGD P15428 1/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14667470 1.00 MAPT (0.60) MAPTPKMCDK5CDK5R1MAPK1
SCHEMBL11963959 1.00 MAPT (0.60) MAPTPKMCDK5CDK5R1MAPK1
SCHEMBL16690263 0.89 SMN1; SMN2 (0.60) MAPTPKMCDK5CDK5R1MAPK1
SCHEMBL92080 0.86 MAPT (0.78) MAPTPKMCDK5CDK5R1MAPK1
SCHEMBL1357956 0.86 MAPT (0.78) MAPTPKMCDK5CDK5R1MAPK1
SCHEMBL9962632 0.84 HPGD (0.59) MAPTPKMCDK5CDK5R1MAPK1
SCHEMBL8768841 0.84 MAPT (0.57) MAPTPKMCDK5CDK5R1MAPK1
SCHEMBL12287274 0.84 HPGD (0.50) MAPTPKMCDK5CDK5R1MAPK1
SCHEMBL213829 0.83 ALDH1A1 (0.51) MAPTPKMCDK5CDK5R1MAPK1
SCHEMBL2045676 0.83 CYP2C19 (0.48) MAPTPKMCDK5CDK5R1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077941-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2012-03-29 US claimed
US-8088868-B2 oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis BRIDGESTONE CORPORATION (JP) 2012-01-03 US claimed
US-20080146745-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2008-06-19 US claimed
US-20240383885-A1 Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose MAKSCIENTIFIC, LLC 2024-11-21 US disclosed
US-12054480-B2 Compounds for treating cannabinoid toxicity and acute cannabinoid overdose MAKSCIENTIFIC, LLC (US) 2024-08-06 US disclosed
US-20220033393-A1 Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose MAKSCIENTIFIC, LLC 2022-02-03 US disclosed
EP-3227018-B1 CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS UNIV VIRGINIA COMMONWEALTH (US) 2021-06-30 EP disclosed
US-10000453-B2 Chelation directed C—H activation reactions catalyzed by solid-supported palladium(II) catalysts VIRGINIA COMMONWEALTH UNIVERSITY (US) 2018-06-19 US disclosed
US-20170362181-A1 CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS VIRGINIA COMMONWEALTH UNIVERSITY 2017-12-21 US disclosed
US-9624171-B2 Photoinitiator mixtures BASF SE (DE) 2017-04-18 US disclosed
US-8541509-B2 Polymers functionalized with protected oxime compounds BRIDGESTONE CORPORATION (JP) 2013-09-24 US disclosed
US-20120077941-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2012-03-29 US disclosed
US-8088868-B2 oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis BRIDGESTONE CORPORATION (JP) 2012-01-03 US disclosed
US-20110218266-A1 PHOTOINITIATOR MIXTURES BASF SE (DE) 2011-09-08 US disclosed
US-20110170209-A1 OXIME ESTER PHOTOINITIATORS BASF SE (DE) 2011-07-14 US disclosed
US-20110134554-A1 PHOTOINITIATOR MIXTURES BASF SE (DE) 2011-06-09 US disclosed
US-20100136467-A1 OXIME ESTER PHOTOINITIATORS BASF SE (DE) 2010-06-03 US disclosed
EP-1702962-B1 Ink composition containing a photo-acid and a photo-base generator and processes using them FUJIFILM CORP (JP) 2008-12-24 EP disclosed
US-20080146745-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2008-06-19 US disclosed
US-4590145-A Photopolymerization initiator comprised of thioxanthones and oxime esters DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1986-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136467-A1 OXIME ESTER PHOTOINITIATORS CHRM4, NR2E3, CYP3A4 MAPT 3589/4885PKM 2429/4885CDK5 1586/4885
US-20240383885-A1 Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose CNR1, CNR2, OPRM1 MAPT 809/4885PKM 3225/4885CDK5 424/4885
US-20170362181-A1 CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS WASF2, SCO2, SOD1 MAPT 2594/4885PKM 3442/4885CDK5 3851/4885
US-20220033393-A1 Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose CNR1, CNR2, OPRM1 MAPT 809/4885PKM 3225/4885CDK5 424/4885
US-10000453-B2 Chelation directed C—H activation reactions catalyzed by solid-supported palladium(II) catalysts WASF2, SOD1, CD274 MAPT 2583/4885PKM 3446/4885CDK5 3889/4885
US-12054480-B2 Compounds for treating cannabinoid toxicity and acute cannabinoid overdose CNR1, CNR2, OPRM1 MAPT 809/4885PKM 3225/4885CDK5 424/4885
US-20110170209-A1 OXIME ESTER PHOTOINITIATORS RAD51, CBR3, CBR1 MAPT 4380/4885PKM 1605/4885CDK5 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.